UCLA partners with Autobahn Labs 'virtual incubator' with drug maker and VC based on new model

According to reporting by Ron Leuty of San Francisco Business Times UCLA has joined into a partnership with German drug maker Evotec SE, Palo Alto Samsara BioCapital, and family fund KCK Ltd. to launch the Autobahn Labs virtual incubator. The novel incubator is based on the concept of a bridge model to fast-track early-stage academic research into startup companies. The partnership is a move away from the short-term ‘value creation’ used in drug-development industry according to venture capitalist Srinivas Akkaraju and CEO of Evotec SE Werner Lanthaler.

According to the article, Amir Naiberg, president and CEO of the UCLA Technology Development Group, discusses the umbrella master agreement implemented between Autobahn and UCLA, which includes licensing, milestone and royalty payments. UCLA will ideally be one of several university partners for Autobahn.

Read more about this unique and innovative partnership here!